Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956382 | 0.90 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2AHIF1APOLB | |
| SCHEMBL6342125 | 0.85 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL3684732 | 0.84 | ALDH1A1 (0.97) | ALDH1A1MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL335280 | 0.82 | POLB (0.97) | ALDH1A1MEN1KMT2AHIF1APOLB | |
| SCHEMBL11620661 | 0.81 | POLB (0.71) | ALDH1A1MEN1KMT2AHIF1APOLB | |
| SCHEMBL6343700 | 0.81 | ALDH1A1 (0.65) | ALDH1A1MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL14003532 | 0.80 | ALDH1A1 (0.69) | ALDH1A1MEN1KMT2APOLBPKM | |
| SCHEMBL4982353 | 0.79 | ALDH1A1 (0.63) | ALDH1A1MEN1KMT2APOLBL3MBTL1 | |
| Hydrochloric Acid SCHEMBL11621347 | 0.79 | POLB (0.74) | ALDH1A1MEN1KMT2AHIF1APOLB | |
| SCHEMBL1557718 | 0.79 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2APOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | ALDH1A1 1939/4885MEN1 2456/4885KMT2A 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.